Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 6/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15844527 | 0.92 | CYP3A4 (0.49) | CYP3A4CYP2C19CYP2C9CCR2TACR1 | |
| SCHEMBL17342647 | 0.79 | CYP3A4 (0.54) | CYP3A4CYP2C19CYP2C9CCR2TACR1 | |
| SCHEMBL20088438 | 0.79 | TACR1 (0.49) | TACR1MTORMLYCD | |
| SCHEMBL20088441 | 0.76 | TACR1 (0.50) | TACR1MTORMLYCD | |
| SCHEMBL4539298 | 0.76 | NAMPT (0.52) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL20088445 | 0.74 | TACR1 (0.47) | TACR1MTORMLYCD | |
| SCHEMBL25780517 | 0.73 | MTOR (0.46) | CCR2TACR1MTORMLYCD | |
| SCHEMBL17437580 | 0.73 | SCN9A (0.42) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL15244712 | 0.71 | TRPV3 (0.59) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL21565748 | 0.71 | TACR1 (0.53) | CCR2TACR1MTORMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | CYP3A4 749/4885CYP2C19 550/4885CYP2C9 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.